C
CLN
vs
W
WIG20
Over the past 12 months, CLN has underperformed WIG20, delivering a return of 0% compared to the WIG20's +28% growth.
Stocks Performance
CLN vs WIG20
Performance By Year
CLN vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Celon Pharma SA
Glance View
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.